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Key Clinical Message
Our objective is to report a case of thyrotoxicosis following pituitary adenec-
tomy for Cushing0s disease, the only pediatric case to our knowledge. No thy-
roid antibodies were detected, and the thyrotoxicosis was successfully treated
for 3 months with no relapse after 5 years of follow-up. The cause of thyrotoxi-
cosis remains unknown.
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Introduction
Cushing0s syndrome results from excess glucocorticoid
steroids and is a rare condition in children and adoles-
cents. Cushing0s disease accounts for over 75% of pedi-
atric causes of Cushing0s syndrome, and it has a male
predominance in prepubertal children but after the onset
of puberty this equals out [1–3]. The disease is most
often caused by a benign micro adenoma in the pituitary
gland, secreting adrenocorticotrophic hormone (ACTH).
The most prominent clinical symptoms and signs in chil-
dren are growth failure, weight gain, virilization, head-
ache, and hypertension [1, 2, 4]. As the disease has
significant morbidity and mortality, early diagnosis is of
utmost importance. To establish the pituitary as the
source of excessive ACTH secretion, diagnosis involves a
series of standardized biochemical and radiological inves-
tigations, such as 24-h urinary sampling for free cortisol,
high-dose dexamethasone suppression test, imaging of the
pituitary gland, and bilateral simultaneous inferior pet-
rosal sinus sampling (BSIPSS) [1, 2, 5]. Transsphenoidal
adenectomy is the primary treatment but in few cases
accompanied by direct irradiation if hypercortisolemia
persists.
Hyperthyroidism refers to overproduction of thyroid
hormone by the thyroid gland, but thyrotoxicosis defines
the clinical and biochemical picture of excessive thyroid
hormones. Symptoms of thyrotoxicosis can be insidious
and include growth acceleration, pubertal delay, ophthal-
mopathy, goiter, tachycardia, weight loss despite of
increased appetite, heat intolerance, proximal muscle
weakness, and changes in behavior. Causes of thyrotoxi-
cosis are many, that is, toxic multinodular goiter, thy-
roiditis, toxic adenoma, and use of drugs, but Grave0s
disease is by far the most common cause [6, 7]. Grave0s
disease affects girls rather than boys (5:1) and has a peak
incidence in adolescents. Most patients have a family his-
tory of autoimmune disease [8]. Grave0s disease is caused
by stimulation of antibodies to the thyroid-stimulating
hormone (TSH) receptor and is diagnosed by high serum
level of thyroxine (T4), triiodothyronine (T3), and low
serum level of TSH as well as presence of antithyroid
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antibodies. Therapy mainly includes antithyroid drugs,
radioactive iodine, and surgery [8–10].
Case Report
An Icelandic girl was referred by the family to a pediatric
endocrinologist at age 12 years because of growth failure.
Growth had become slower the past 2.5 years (from 0 SD
to 1 SD) as well as she had gained weight (from 0 SD
to +1 SD). She had become lethargic, her face had
become more swollen, and she had trouble with acne.
Endocrine tests showed a substantial increase in both
morning serum cortisol, 864 nanomol/liter (nmol/L) (ref-
erence range 193–773 nmol/L) and urine cortisol,
553 nmol/24 h (in totally 1.06 L urine) (reference range
for age 9–12 years 7.2–102 nmol/24 h). Overnight high-
dose dexamethasone test indicated a possible Cushing0s
disease with serum cortisol before suppression measuring
530, 691, and 754 nmol/L and after suppression 78, 65,
and 62 nmol/L and ACTH before suppression measuring
40, 47, and 43, and after suppression 12, 13, and 16 (pre-
pubertal reference range 1.55–6.2 pmol/L) (three sets of
blood tests, before and after high-dose dexamethasone
test). MRI studies did not clearly demonstrate a pituitary
adenoma and were seen as normal. A sinus petrosus
catheterization on the other hand showed a high pituitary
secretion of ACTH, especially on the right side as can be
seen from following test results: pretest: right-side sample
(RS) 224 and 348 nmol/L, left-side sample (LS) 71 and
93 nmol/L, and peripheral sample (PS) 11 and 12 nmol/L;
after 5 min: RS 2790 nmol/L, LS 2279 nmol/L, PS 16 nmol/
L; after 10 min: RS 2990 nmol/L, LS 3370 nmol/L, PS
37 nmol/L; after 15 min: RS >4000 nmol/L, LS 1900 nmol/
L, PS 55 nmol/L; after 20 min: RS >4000 nmol/L, LS
missing sample data, PS 63 nmol/L. For the catheteriza-
tion, the patient received iopromide (Ultravist), 75 mL in
total that makes up for 11 g of iodine. Subsequently, the
girl underwent transsphenoidal surgery 3 months later
where the pituitary was sliced from the right side and
a 3 mm superficial adenoma was found and removed.
Postoperatively, she was treated with hydrocortisone iv
and then cortisone acetate po, which went well and the
girl was discharged a few days later.
A week after surgery, she started to have headaches as
well as loss of appetite, diarrhea, and vomiting. At first,
this was thought to be myalgia and gastritis due to sur-
gery and she was administered extra hydrocortisone and
esomeprazole with little effect. Nearly 2 months later, she
was still having these symptoms in addition to tachycar-
dia and angina-like symptoms. Following blood tests, the
girl was diagnosed with thyrotoxicosis with serum TSH
measuring 0.02 milli-international units of activity
(mIU)/L (reference range 0.3–4.2 mIU/L), free T4
measuring 63.9 picomol (pmol)/L (reference range
12–22 pmol/L) and free T3 measuring 24.8 pmol/L
(3.5–6.7 pmol/L). Antibodies were negative, and she was
successfully treated with carbimazole and propranolol.
The thyrotoxicosis resolved after 3 months with no fur-
ther treatment needed. Thyroid ultrasound performed
one and a half year after the resolution of the thyrotoxi-
cosis showed an enlarged lucent thyroid with a few ill-
defined nodules. The cause of thyrotoxicosis was not
established and remains unknown.
Discussion
To our knowledge, a pediatric case of thyrotoxicosis
developing after transsphenoidal surgery has not yet been
reported. There are however a few cases of adults devel-
oping thyrotoxicosis after surgery for Cushing0s syn-
drome. Yamakita et al. [11] report a silent thyroiditis
after unilateral adrenalectomy in a patient with Cushing0s
syndrome 9 months after surgery. They speculate that
exposure to a large amount of endogenous and supple-
mentary glucocorticoid protected the patient from thyroid
antigens and that tapering of the prednisolone caused
exacerbation of immune responses resulting in thyroid
dysfunction. Another case report tells of an adult develop-
ing transient Grave0s disease after surgery for Cushing0s
disease and the authors presume that a latent autoim-
mune process in the thyroid, suppressed by hypercorti-
solism, developed into overt Grave0s disease after abrupt
reduction of plasma glucocorticoid levels after surgery
[12]. Unlike our case, both of these cases postulate an
antibody-positive thyroid dysfunction, and therefore, this
pediatric case is unique. Iodinated contrast medium is
known to induce thyrotoxicosis in adults but is very rare
[13–15]. In this case, the first symptoms of thyrotoxicosis
developed approximately 2 months after the use of iodi-
nated contrast medium, and according to Conn et al.
[16], the contrast may affect the thyroid as long as
8 weeks postinjection. Contrast medium injection does
however not affect thyroid function tests (TFT) in
patients with a normal thyroid. Patients at risk of devel-
oping thyrotoxicosis after contrast medium injection are
patients with Grave0s disease and multinodular goiter with
thyroid autonomy, especially elderly patients and patients
living in areas of iodine deficiency [13, 17]. Iceland is
considered an area without iodine deficiency, and it has
been established that the girl did not have Grave0s disease
as she was antibody negative. She did however have an
enlarged thyroid with a few ill-defined nodules, whether
that has any clinical importance has not been established.
The only cases of contrast induced thyrotoxicosis in
patients with autonomous nodules in the thyroid gland
are of elderly patients, and no pediatric cases have been
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reported to our knowledge. The amount of iodine that
the girl received is also considerably low in relation to the
adult cases presented. The cause of thyrotoxicosis there-
fore still remains unknown. The thyrotoxicosis needed
short treatment with a thyreostatic drug (3 months), and
now 5 years after surgery, there are no signs of reoccur-
rence of thyrotoxicosis, making antibody caused disease
very unlikely.
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